TMCnet News
PWRM.OB, NASDAQ:NHWK and NYSE:PFE Informational Updates On Medical Companies.Stock-PR Reporting FREE Daily Stock Alerts From Stock-PR.com ________________________________________ Power 3 Medical Products Inc. (PWRM.OB) BC-SeraPro was developed and its performance characteristics determined by PWRM Laboratories. BC-SeraPr is an ideal diagnostic test to evaluate breast cancer abnormalities found by mammogram or breast examination. PWRM strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. BC-SeraPro could detect the disease at a point when treatment is more effective, less expensive, or both. The test would distinguish women who should have a biopsy from those who can safely avoid one. BC-SeraPro is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will monitor the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer. The BC-SeraPro? test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to the PWRMs' patient database. PWRM's NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Power3's NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer's disease. With these results, PWRM's NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms. Power3 Medical Products, Inc., a development stage company, engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimers disease, and Parkinsons disease. Its product candidates include BC-SeraPro, a blood serum protein breast cancer test for the diagnosis of breast cancer and to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. NightHawk Radiology Holdings, Inc. (Nasdaq:NHWK), the leading provider of radiology solutions to radiology groups across the United States, announced that, effective June 30, 2010, it has completed its settlement transaction with St. Paul Radiology, P.A. As a result of the settlement transaction, NightHawk sold to a third party its ownership interests in Midwest Physicians Services, LLC and Emergency Radiology Services, LLC, the parties settled all disputes between them and terminated all of the agreements entered into in connection with the July 2007 transaction between the parties. Consistent with NightHawk's previous disclosures in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2010 filed with the Securities and Exchange Commission on May 7, 2010, NightHawk will receive aggregate consideration of $26 million in connection with the settlement transaction, $12 million of which NightHawk received at closing and $14 million of which will be paid to NightHawk over the next four years. In addition, NightHawk expects to realize tax savings of approximately $10 million related to the settlement, for a total expected value of the settlement of approximately $36 million over four years. In order to complete the settlement transaction, NightHawk received consent from its lenders under its credit agreement. In connection with that consent, on June 30th, NightHawk paid to the Lenders a principal repayment of $26 million. Also, as part of the consent, NightHawk has agreed to make an additional principal repayment of $10 million on or before June 30, 2011, for a total expected principal repayment of $36 million. Additional details regarding the settlement transaction, a description of the material agreements entered into in connection with the transaction, NightHawk's principal payment to its lenders and other financial information related to the transaction will be filed on a Current Report on Form 8-K on or before Wednesday, July 7, 2010. NightHawk Radiology is leading the transformation of the practice of radiology by providing high-quality, cost-effective solutions in the U.S. NightHawk provides the most complete suite of solutions, designed to increase efficiencies and improve the quality of patient care and the lives of radiologists. NightHawk's team of U.S. board-certified, state-licensed, and hospital-privileged physicians are located in the United States, Australia, and Switzerland. They provide services 24 hours a day, 7 days a week, to approximately 1,600 sites, representing approximately 26 percent of all U.S. hospitals. For more information, visit http://www.nighthawkrad.net. Pfizer (NYSE:PFE) recently announced that it will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders. For the first time, these users can directly access and download the Patient Health Questionnaire (PHQ) and the General Anxiety Disorder questionnaire (GAD-7) without copyright restriction and at no charge, providing unprecedented access to these valuable and widely used tools for evaluating certain mental disorders. "By providing unrestricted access, Pfizer is encouraging broader usage of these important patient assessment aids, which we know will help many healthcare providers and their patients," said Freda C. Lewis-Hall, M.D., senior vice president and chief medical officer at Pfizer. "We are listening to the needs of the mental health community and doing what we can to provide the tools needed to make the best possible healthcare decisions." The PHQ and GAD scales are quick, efficient, validated methods to assist physicians in diagnosing and monitoring their patients. PHQ-9, a widely used questionnaire, is self-administered and utilizes a scoring method to specifically measure depression-related symptoms. In less than a decade, the PHQ-9 has become commonly used by both clinicians and researchers in large federally sponsored U.S. surveys and has been adopted as a standard measure for depression risk and severity by the Veterans Administration, Department of Defense and several integrated health care systems and public health departments as well as the United Kingdom's National Health Service. More than a decade ago, Pfizer, along with research partners Robert Spitzer, M.D. and Janet Williams, D.S.W. from Columbia University and Kurt Kroenke, M.D. from Indiana University, recognized the need for and supported the independent development of dimensional measurement tools for mental disorders to be used by health care professionals. The four original studies that validated the tools represented nearly 10,000 patients. Between 1999 and 2009, more than 560 publications on these assessment aids have been identified. The PHQ and GAD instruments, including different variations and translations in nearly 80 languages, are available at www.phqscreeners.com. The site also provides comprehensive instruction documents, articles, a bibliography and a direct point of contact e-mail address. To learn more about Pfizer's commitments, please visit: www.pfizer.com. Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB) Sign Up For Free Stock Alerts At http://stock-pr.com/signup ________________________________________ Be Sure To Visit stock-pr.ning.com ******************************** The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments. |